Nextcure Inc (NXTC)

$0.36 +0.03 (7.89%)
Market Cap 10.13M
Revenue (ttm) 0.00
Net Income (ttm) -55.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 236,500
Avg Vol 132,406
Day's Range N/A - N/A
Shares Out 28.05M
Stochastic %K 64%
Beta 0.89
Analysts Strong Sell
Price Target $3.33

Latest News on NXTC

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 7:00 AM EDT - 17 days ago

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Mar 6, 2025, 4:05 PM EST - 6 weeks ago

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

Jan 10, 2025, 8:05 AM EST - 3 months ago

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

NextCure Announces Acceptance of IND Application for LNCB74

Dec 10, 2024, 8:05 AM EST - 4 months ago

NextCure Announces Acceptance of IND Application for LNCB74

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 5 months ago

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Nov 19, 2024, 8:05 AM EST - 5 months ago

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 4:05 PM EST - 5 months ago

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

Nov 5, 2024, 4:05 PM EST - 5 months ago

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 7 months ago

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

Sep 16, 2024, 8:05 AM EDT - 7 months ago

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 20, 2024, 4:10 PM EDT - 10 months ago

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

May 30, 2024, 4:05 PM EDT - 11 months ago

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Apr 24, 2024, 4:05 PM EDT - 1 year ago

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Apr 8, 2024, 7:00 AM EDT - 1 year ago

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Apr 4, 2024, 7:05 AM EDT - 1 year ago

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 7:00 AM EDT - 1 year ago

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 8:55 AM EDT - 1 year ago

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Mar 5, 2024, 8:05 AM EST - 1 year ago

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Jan 18, 2024, 4:05 PM EST - 1 year ago

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Dec 21, 2023, 7:05 AM EST - 1 year ago

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

NextCure Provides Year-End Clinical Pipeline Updates

Dec 14, 2023, 6:45 AM EST - 1 year ago

NextCure Provides Year-End Clinical Pipeline Updates

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 7:00 AM EST - 1 year ago

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

Nov 15, 2023, 4:05 PM EST - 1 year ago

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 2, 2023, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

Oct 17, 2023, 8:05 AM EDT - 1 year ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

Sep 26, 2023, 4:05 PM EDT - 1 year ago

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

Sep 12, 2023, 8:05 AM EDT - 1 year ago

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

Sep 7, 2023, 4:05 PM EDT - 1 year ago

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

Sep 5, 2023, 4:05 PM EDT - 1 year ago

Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 7:00 AM EDT - 1 year ago

NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

Jun 21, 2023, 4:05 PM EDT - 1 year ago

NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

NextCure to Present at the JMP Securities Life Sciences Conference

May 9, 2023, 7:00 AM EDT - 2 years ago

NextCure to Present at the JMP Securities Life Sciences Conference

NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

May 4, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

Apr 11, 2023, 7:00 AM EDT - 2 years ago

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2022 Financial Results

Mar 2, 2023, 4:05 PM EST - 2 years ago

NextCure Provides Business Update and Reports Full Year 2022 Financial Results

NextCure to Present at SVB Securities Global Biopharma Conference

Feb 7, 2023, 7:00 AM EST - 2 years ago

NextCure to Present at SVB Securities Global Biopharma Conference

NextCure to Present at Upcoming Investor Conferences

Nov 22, 2022, 8:00 AM EST - 2 years ago

NextCure to Present at Upcoming Investor Conferences

NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

Nov 15, 2022, 4:30 PM EST - 2 years ago

NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Nov 7, 2022, 8:05 AM EST - 2 years ago

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

NextCure Provides Update and Reports Third Quarter 2022 Financial Results

Nov 3, 2022, 4:15 PM EDT - 2 years ago

NextCure Provides Update and Reports Third Quarter 2022 Financial Results

NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2022, 9:15 AM EDT - 2 years ago

NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting

NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

Oct 27, 2022, 4:05 PM EDT - 2 years ago

NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Oct 5, 2022, 8:15 AM EDT - 2 years ago

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

Oct 4, 2022, 4:05 PM EDT - 2 years ago

NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

NextCure to Present at the Ladenburg Thalmann Healthcare Conference

Sep 22, 2022, 8:00 AM EDT - 2 years ago

NextCure to Present at the Ladenburg Thalmann Healthcare Conference

NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results

Aug 4, 2022, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results

NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation

Jul 6, 2022, 8:00 AM EDT - 3 years ago

NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation

NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

Jun 27, 2022, 8:00 AM EDT - 3 years ago

NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM